Paul Ryan joins Board

JANESVILLE, Wis., Aug. 26, 2019 – SHINE Medical Technologies, LLC today announced the appointment of Paul D. Ryan to the company’s board of directors.

$15-million DOE/NNSA award for medical isotope

JANESVILLE, Wis., Aug. 9, 2019 – SHINE Medical Technologies LLC today announced it has received a $15-million award from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA). The award was made by the agency as part of its effort to establish a reliable, U.S.-produced supply of molybdenum-99 (Mo-99), the most commonly used medical isotope, without the use of highly enriched uranium.

SHINE files application with NRC

July 22nd, 2019 – JANESVILLE, WI – SHINE Medical Technologies LLC today announced that the company has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes, including molybdenum-99 (Mo-99), iodine-131 and xenon-133, at its production facility in Janesville, WI. 

Technology Demonstration Validates Business Case

Phoenix Neutron Generator Completes Milestone Validating Output and Reliability June 19th, 2019 – Janesville, WI – SHINE Medical Technologies, a Janesville, WI medical isotope production company, announced the completion of an important milestone validating the SHINE...

Production Facility Groundbreaking

Production Facility Groundbreaking May 9th, 2019 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, broke ground today on their first...

SHINE Licenses Lu-177 Separation Process

Novel Separation Method Accelerates SHINE’s Path to Market for Cancer Treatment Isotopes May 15th, 2019 – Prague, Czechia – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin company dedicated to being the world leader in the safe, clean, affordable production of...